SAC Capital Advisors LP bet big on a firm called Ardea Biosciences Inc. at the
beginning of last year.
Diving into a small stock it never before reported owning, the hedge-fund firm bought 1.2 million shares, which at the end of the first quarter were valued at $26.7 million.
Three weeks later, a stake of that size was worth $12.1 million more. On April 23, Britain's AstraZeneca PLC said it would buy Ardea, the culmination of two months of
confidential negotiations. The deal sent the stock soaring 52% that day.
三周后,这笔投资的价值激增1,210万美元。去年4月23日,英国的阿斯利康(AstraZeneca PLC)表示将收购Ardea。这一结果的达成经过了两个月的秘密谈判。消息公布当天,Ardea股价大涨52%。
Such high-stakes trading over the years has made SAC the subject of
admiration and envy on Wall Street. The hedge-fund firm